Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III QL2108 vs Dupixent in adults with moderate-to-severe atopic dermatitis
CTR20250820Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL2108 in atopic dermatitis (AD), sponsored by Qilu Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
QL2108
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20250820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250820.